Glytactin EfficiEncy in Non or Insufficiently Treated Adult PHENylketonuria Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-19

Study Completion Date

2022-09-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phenylketonuria is the most common inherited metabolic disease in France and is screened for neonatal exposure. Management consists of a strict and restrictive hypoproteic diet and the intake of amino acid substitutes and dietary supplements free of phenylalanine.One of the major difficulties, which is the source of many treatment failures, is the inappetence of the amino acid supplements required during a strict hypoproteic diet. New formulations, Glycomacropeptides (GMP), have recently appeared and are considered more palatable than conventional amino acid mixtures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Protein Requirements in Adults With Phenylketonuria (PKU)

NCT03939052

Phenylketonuria

COMPLETED NA

Evaluation of PKU Start

NCT03058848

Phenylketonuria Inborn Errors of Metabolism

COMPLETED NA

Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria

NCT03333720

Phenylketonurias

WITHDRAWN NA

Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.

NCT04433728

Phenylketonurias

UNKNOWN

Early Dietary Treated Patients With Phenylketonuria Can Achieve Normal Growth and Mental Development.

NCT04302194

Phenylketonurias

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phenylketonuria is the most common inherited metabolic disease in France and is screened for neonatal exposure. Management consists of a strict and restrictive hypoproteic diet and the intake of amino acid substitutes and dietary supplements free of phenylalanine. If the benefits of treatment are indisputable in children in terms of cognitive prognosis, this benefit is discussed once brain development is complete, especially as many adult patients are no longer treated. However, cognitive, neurological and reversible white matter disorders undergoing treatment are increasingly reported in adult phenylketonurics. As a result, recent European recommendations advocate the maintenance of life-long treatment. One of the major difficulties, which is the source of many treatment failures, is the inappetence of the amino acid supplements required during a strict hypoproteic diet. New formulations, Glycomacropeptides (GMP), have recently appeared and are considered more palatable than conventional mixtures.

PRIMARY OBJECTIVE:

Demonstrate a better metabolic balance under GMP treatment than a conventional amino acid mixture in adult phenylketonuric patients when resuming treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Phenylketonuria Non Treated Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicenter randomized controlled trial performed in open and 2 parallel groups: "GMP" versus "amino acids" group

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GMP - Dietary Supplement for PKU patients

Glycomacropeptides -GMP Glytactin

Group Type EXPERIMENTAL

Dietary Supplement for PKU patients

Intervention Type DIETARY_SUPPLEMENT

For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.

Control -Amino acids mixtures

Mixtures of conventional amino acids.

Group Type ACTIVE_COMPARATOR

Dietary Supplement for PKU patients

Intervention Type DIETARY_SUPPLEMENT

For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dietary Supplement for PKU patients

For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age ≥18 years on an empty stomach
* Phenylketonuric patient Patient with Phenylalaninemia ≥ 900μmol / L on a blotter performed during the screening period (or average of blotter results ≥900 μmol / L if several blotters performed during the screening period)
* Untreated or insufficiently treated patient: not taking or insufficiently Dietary foods for special medical purposes for his PKU, regardless of diet, at the discretion of the investigator
* Patient having signed a free, informed and express consent
* Patient requiring a diet restricted in natural proteins

Exclusion Criteria

* Protected patient: court bail
* Patient with concomitant diseases / conditions that may compromise the study, at the discretion of the investigator
* Participated in a clinical trial or trial to evaluate PKU foods or treatments in the last 7 days prior to inclusion or planned during the next 6 months
* Participation in an interventional study with health products during the next 6 months
* Pregnancy project within 6 months, pre-conception diet, pregnancy or breastfeeding
* Refusal to consume only validated complements for the protocol
* Phenylketonuria undergoing treatment with BH4
* Allergy to the product under study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No